8 studies found for:    cholangiocarcinoma | United States, North Carolina
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Conditions: Adenocarcinoma of the Extrahepatic Bile Duct;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma With Squamous Metaplasia of the Gallbladder;   Anaplastic Carcinoma of the Gallbladder;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: sorafenib tosylate;   Drug: erlotinib hydrochloride
2 Completed
Has Results
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
Interventions: Drug: capecitabine;   Drug: gemcitabine hydrochloride
3 Active, not recruiting S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
Interventions: Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
4 Recruiting CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
5 Recruiting Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Conditions: Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Childhood Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage D Adult Primary Liver Cancer (BCLC);   Stage II Gallbladder Cancer;   Stage III Childhood Liver Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Childhood Liver Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: trametinib;   Drug: leucovorin calcium;   Drug: fluorouracil;   Drug: capecitabine;   Other: laboratory biomarker analysis
6 Completed Biological Therapy in Treating Patients With Metastatic Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Head and Neck Cancer;   Liver Cancer;   Lung Cancer;   Metastatic Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Testicular Germ Cell Tumor
Intervention: Biological: CEA RNA-pulsed DC cancer vaccine
7 Completed Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Head and Neck Cancer;   Liver Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Testicular Germ Cell Tumor
Intervention: Biological: TRICOM-CEA(6D)
8 Completed Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium

Indicates status has not been verified in more than two years